

## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Committee: Patient Engagement Advisory Committee  Meeting Date: October 6, 2021  I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: On October 6, 2021, the Committee will discuss and make recommendations on the topic "Medical Device Recalls." Once a medical device is available in the U.S. marketplace and in widespresuse, unforeseen problems can sometimes lead to a recall. When a device is defective or potentially harm recalling that product—removing it from the market or correcting the problem—is the most effective means for protecting the public. I may be considered for participation in the advisory committee meeting described above.    Type of Interest	Name of Advisory Committee Member: Shelby Reed, Ph.D., RPh			
I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: On October 6, 2021, the Committee will discuss and make recommendations on the topic "Medical Device Recalls." Once a medical device is available in the U.S. marketplace and in widespreuse, unforeseen problems can sometimes lead to a recall. When a device is defective or potentially harm recalling that product—removing it from the market or correcting the problem—is the most effective means for protecting the public. I may be considered for participation in the advisory committee meeting described above.    Type of Interest	Committee: Patient Engagement Advisory Committee			
agenda item: On October 6, 2021, the Committee will discuss and make recommendations on the topic "Medical Device Recalls." Once a medical device is available in the U.S. marketplace and in widespresuse, unforeseen problems can sometimes lead to a recall. When a device is defective or potentially harm recalling that product—removing it from the market or correcting the problem—is the most effective means for protecting the public. I may be considered for participation in the advisory committee meeting described above.    Type of Interest	Meeting Date: October 6, 2021			
I. Personal/Immediate Family  Stockholdings/Investment Affected firms (six) Combined value between \$50,000 a \$70,000  II. Other Imputed Interests  None  I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiv allowing me to participate in the meeting described above. I understand that without public disclosure of the interests, I will not participate in the advisory committee meeting described above.	agenda item: On October 6, 2021, the "Medical Device Recalls." Once a suse, unforeseen problems can somet recalling that product—removing it means for protecting the public. I may	ne Committee will discuss and medical device is available in times lead to a recall. When a different the market or correcting to	make recommendations on the topic the U.S. marketplace and in widespread levice is defective or potentially harmful, the problem—is the most effective	
Stockholdings/Investment  Affected firms (six)  Combined value between \$50,000 a \$70,000  II. Other Imputed Interests  None  I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiv allowing me to participate in the meeting described above. I understand that without public disclosure of the interests, I will not participate in the advisory committee meeting described above.	Type of Interest	<u>Nature</u>	Magnitude	
II. Other Imputed Interests  None  I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiv allowing me to participate in the meeting described above. I understand that without public disclosure of the interests, I will not participate in the advisory committee meeting described above.	I. Personal/Immediate Family			
None  I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiv allowing me to participate in the meeting described above. I understand that without public disclosure of the interests, I will not participate in the advisory committee meeting described above.	Stockholdings/Investment	Affected firms (six)	Combined value between \$50,000 and \$70,000	
I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiv allowing me to participate in the meeting described above. I understand that without public disclosure of the interests, I will not participate in the advisory committee meeting described above.	II. Other Imputed Interests			
allowing me to participate in the meeting described above. I understand that without public disclosure of the interests, I will not participate in the advisory committee meeting described above.	None			
Signature Date	allowing me to participate in the meet interests, I will not participate in the a	ing described above. I understand described above in described above. I understand described above. I understand described above.	nd that without public disclosure of these cribed above.  9/7/2021	